Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.

Autor: Ciruelos E; Medical Oncology Unit, Hospital 12 de Octubre, Madrid, Spain., García-Sáenz JÁ; Medical Oncology Unit, Hospital Clínico San Carlos, Madrid, Spain., Gavilá J; Medical Oncology Unit, Fundación Instituto Valenciano de Oncología, Valencia, Spain., Martín M; Medical Oncology Unit, Hospital Gregorio Marañón, Madrid, Spain., Rodríguez CA; Medical Oncology Unit, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain., Rodríguez-Lescure Á; Medical Oncology Unit, Hospital General Universitario de Elche, Alicante, Spain. alescure@geicam.org.
Jazyk: angličtina
Zdroj: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Jul; Vol. 26 (7), pp. 1539-1548. Date of Electronic Publication: 2024 Feb 09.
DOI: 10.1007/s12094-024-03383-x
Abstrakt: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate that targets human epidermal growth factor receptor 2 (HER2) and has shown promising results in the treatment of advanced/metastatic breast cancer. The objective of this report is to provide guidance on the prophylaxis, monitoring, and management of adverse events (AEs) in patients with breast cancer treated with T-DXd, and to emphasize that proper management of AEs is needed to optimize the effectiveness of T-DXd treatment and reduce the number of discontinuations. The article covers various aspects of T-DXd treatment, including its clinical efficacy, safety profile, and dosing considerations, and provides practical recommendations for managing AEs, such as nausea/vomiting, interstitial lung disease, and hematologic toxicity. Although there are still many knowledge gaps about the cause and incidence of AEs in real-world patients, this document may serve as a valuable resource for clinicians who are involved in the care of breast cancer patients receiving T-DXd treatment.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: